Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2020-11-09 Regulatory Filings
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
CARMA Cell Therapies at SITC 2020
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces that MaxCyte, Inc. will share research results at an upcoming medical conference (SITC 2020). It does not contain financial statements, audit reports, or other specific corporate filings, but rather serves as a general regulatory announcement regarding company activities. Therefore, it falls under the RNS (Regulatory Filings) category.
2020-11-09 English
Presentations at Upcoming Virtual IR Conferences
Regulatory Filings Classification · 98% confidence The document is a short announcement (RNS) from MaxCyte, Inc. regarding upcoming investor conference presentations. It does not contain the actual presentation slides or a full report, but rather notifies the market of the company's participation in scheduled events. As it is a general regulatory announcement that does not fit into specific categories like 'Investor Presentation' (which would be the slides themselves) or 'Report Publication Announcement', it falls under the 'Regulatory Filings' (RNS) category.
2020-11-09 English
Result of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Result of AGM' and explicitly states that it is an announcement regarding the results of the Annual General Meeting held on 30th October 2020, confirming that all resolutions were duly passed. This falls directly under the definition of a Declaration of Voting Results.
2020-11-02 English
Disclosure of Remuneration for Non-Audit Services
Remuneration Information Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement from MaxCyte, Inc. regarding a clarification of remuneration paid to auditors for non-audit services. While it mentions remuneration, it is not a formal executive compensation report (DEF 14A) but rather a regulatory disclosure update provided to investors ahead of an AGM. Since it is a general regulatory announcement that does not fit into specific categories like financial reports or proxy statements, it is classified as a Regulatory Filing (RNS).
2020-10-22 English
Notification of AGM and Audit Declaration
AGM Information Classification · 98% confidence The document is a short announcement (under 5,000 characters) from MaxCyte, Inc. regarding the distribution of formal notice and resolutions for their upcoming Annual General Meeting (AGM). It explicitly states that these documents have been circulated to shareholders and are available on the company's website. According to the 'Menu vs Meal' rule, since this is an announcement of the availability of meeting materials rather than the materials themselves, it is classified as a Report Publication Announcement (RPA).
2020-10-14 English
MaxCyte announces leadership appointments
Board/Management Information Classification · 100% confidence The document is a press release issued via the London Stock Exchange's RNS (Reach) service. It explicitly announces the promotion of Brad Calvin to Chief Commercial Officer and the appointment of two new Vice Presidents at MaxCyte, Inc. Since the document focuses entirely on changes to the company's senior management team, it falls under the 'Board/Management Information' category.
2020-10-13 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.